A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
Phase 1
10
about 1.7 years
21–80
1 site in MO
About this study
This trial is testing if drug (NIO752) reduces production of tau, a protein that builds up in the brain and causes damage in Alzheimer's disease. The goal is to see if NIO752 can help slow down this process.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take NIO752
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Compare rates of tau synthesis and clearance in sporadic AD and ADAD, Comparison of number of Adverse Events reported between participants receiving one dose of NIO752 versus those receiving two doses of NIO752., Number of participants with adverse events [safety and tolerability]
Neurology